Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study

OBJECTIVE: Since 2016, the Chinese government has been regularly implementing the National Reimbursement Drug List Negotiation (NRDLN) to improve the accessibility of drugs. In the second round of NRDLN in July 2017, 18 anticancer drugs were included. This study analyzed the impact of the NRDLN on t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hong, Zhu, Jingmin, Zhou, Yingyu, Shan, Linghan, Li, Cui, Cui, Yu, Kang, Zheng, Jiao, Mingli, Liu, Huan, Gao, Lijun, Wu, Qunhong, Hao, Yanhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283976/
https://www.ncbi.nlm.nih.gov/pubmed/35844892
http://dx.doi.org/10.3389/fpubh.2022.921093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283976/
https://www.ncbi.nlm.nih.gov/pubmed/35844892
http://dx.doi.org/10.3389/fpubh.2022.921093

Ejemplares similares